卖什么
We build better immunotherapies
商业模式拆解
工作流：什么输入变成什么输出？
Cis-targeted molecule engages an immunomodulatory receptor and a target on the same immune cell, so IL-2 activates only CD8+ effector T cells; being tested in Phase 1a/1b trial.
经济账：省了什么，怎么收费？
未核实Pre-revenue therapeutics; value comes from clinical milestones, partnerships and licensing (e.g. clinical trial collaboration and supply agreement announced Jan 2025).
渠道：怎么接触到客户？
未核实Not sold; drug candidates advanced through clinical trials and pharma collaborations.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2019 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.